Changing to Avastin could save NHS £100m a year

Changing to Avastin could save NHS £100m a year

Posted on 25th November 2014

The drug Avastin has been in the newscalling for its use in the UK in a bid to save millions each year.

eye-care

Popular in the US, Avastin is used for patients with age-related macular degeneration (AMD). It has been on the market for years, gone through all the testing and has been proven to be as effective as Lucentis, the NHS approved drug for the same condition. The difference is cost. Lucentis typically costs around £700 per treatment, compared to Avastin which is about £70. Yet red tape seems to be halting its use.

It is currently unlicensed in the UK so should anything go wrong with its use, the practitioner may not be legally covered. However, in times of austerity and it is perhaps time for the NHS to move forward and license its use.


Related Posts

We won!

16th April 2018

We are thrilled to announce that we have won the Practice Growth Award at the national UK Optician Awards. The highly regarded awards, recognise excellence in the optical industry.  This award is ...

Read more

Further qualifications for our optometrists

27th March 2018

We’re delighted to share the news that Claire Keith recently completed her professional certificate in Medical Retina. The course has allowed Claire to further her knowledge of common medical retina...

Read more

Spring/summer eyewear trends

12th March 2018

The weather says winter isn’t over yet but that shouldn’t stop you getting spring/summer ready. And what better way to update your look than with exciting new eyewear? This style staple can transf...

Read more

Cameron Optometry first practice to welcome most advanced scanner available worldwide

22nd February 2018

This week, we welcome the Optos California scanner to the practice, continuing our commitment to ensure we always have the latest technology available. We are the first optometry practice in Scotland ...

Read more